China Junshi's potential COVID drug shows promise in small trial – Reuters.com

China Junshi's potential COVID drug shows promise in small trial – Reuters.com

BEIJING, May 18 (Reuters) – An antiviral oral drug being co-developed by Shanghai Junshi Biosciences’ (688180.SS) subsidiary and other Chinese institutes showed early promise in speeding the clearing of virus in COVID-19 patients, according to a small clinical trial.
The drug, called VV116, is a derivative of Gilead Sciences Inc’s (GILD.O) COVID drug remdesivir and was approved for use in moderate to severe cases in Uzbekistan last year.
The viral shedding period, defined by its trial researchers as the duration between the first positive COVID test result and the first negative one, was 8.56 days for participants who took the experimental treatment within five days from the first positive test result.
That was shorter than 11.13 days seen in the control group, peer-reviewed data showed.
The trial involved 136 mild or moderate adult COVID infections recruited in March in China. Participants were given either the five-day course oral drug along with standard treatment or standard treatment only, researchers said in a paper published in the journal Emerging Microbes & Infections.
Overall, there was no significant difference between the viral shedding period for those who took VV116 more than five days after first positive result and the control group.
Limitations of the study include the small trial size and a higher portion of participants in the control group reporting symptoms, which could result in potential bias that researchers had to adjust with statistic model, the paper said.
The drug is undergoing a Phase III trial to evaluate its efficacy in mild to moderate patients in comparison with Pfizer Inc’s (PFE.N) oral pill Paxlovid, and a separate Phase III trial in moderate to severe cases.
China has approved Paxlovid as well as Brii Biosciences Ltd’s (2137.HK) antibody-based injection for mild and moderate COVID patients with high risk of progressing to severe conditions.
Our Standards: The Thomson Reuters Trust Principles.
Sign up to our health newsletter to keep up with the latest healthcare trends and pharmaceutical news.
Subscribe to our newsletter to get all the news you need to start your day.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world’s media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All rights reserved

source


Leave a Reply

Your email address will not be published.